injection of 0

injection of 0.03, 0.06, or 0.09 mg/kg flunitrazepam dissolved in 0.5% tween-80 in isotonic saline, or an equivalent volume of 0.5% tween-80 in isotonic saline. a delivery method through which the druggable compound may reach itsin vivotarget. Small molecule therapeutics prescribed to modify mental or psychological states require a mechanism for transport across the blood-brain barrier when their site of action is within the central nervous system (CNS). For example, catecholamine and serotonin mimetics, which often Ropinirole contain the arylethylamine moiety common to monoamine neurotransmitters, function as agonists or antagonists of the respective neurotransmitter system. However, such direct manipulation of neural pathways by CNS-targeted therapies may incur noticeable side effects. To treat drug abuse, other routes have been explored for affecting the signaling networks altered by the illicit substance. For example, small molecule therapies that compete for the same CNS site may block drug binding. This technique either circumvents the corresponding drug high or overdose, or it supports user abstinence by supplying a drug substitute which endows a similar high of diminished intensity but prolonged duration. The latter instance has been used with limited success in drug-specific cases for the management of addiction (e.g., methadone, buprenorphine, and naloxone to treat heroin abuse). However, this strategy is not without drawbacks, with the most notable being the inherent addictive quality of the therapeutic agent. Further diminishing the utility of small molecule therapeutics is their incompatibility with prophylactic treatment. In this study, we sought to demonstrate the use of immunopharmacotherapy as a prophylactic anti-drug therapeutic with the capacity to stave off drug-induced cognitive impairment despite its exclusion from the CNS. Whereas immunopharmacotherapy has been validated within the scenario of attenuating the psychomotor symptoms of drug intoxication from a comparatively large drug dose that potentially overwhelms the drug-binding capacity of the administered mAbs, the opposite scenario is rarely examined. As an immunotherapeutic target, benzodiazepines contrast with the traditional psychostimulants because a comparatively small number of drug molecules escaping mAb-mediated sequestration may precipitate measurable changes in cognitive processes. Protection from benzodiazepines does not probe the efficacy of a maximum mAb dose against a potential molar excess of drug, but instead it examines whether the rate of mAb-mediated drug scavenging in the periphery is sufficient to block even a minimal amount of drug from entering the CNS. To explore passive immunization against a highly potent abused small molecule, a hapten against flunitrazepam was designed, and the monoclonal antibody (mAb) therapy evaluated for its ability to prevent flunitrazepam-induced memory deficits. To date, Ropinirole the implementation of passive immunization strategies has been limited in scope despite a major recognized Ropinirole benefit over other anti-addiction therapies (methadone maintenance, nicotine patch). In particular, immunization incurs minimal physiological consequences when drug use or exposure is avoided. Currently, attempts to diminish drug dependence or attenuate drug inebriation with anti-drug mAbs have been explored for morphine, PCP, cocaine, methamphetamine, mescaline, and nicotine1-4. These investigations into mAb-mediated pharmacokinetic antagonism have focused on the attenuation of drug self-administration, restoration or protection of basic motor skills, prevention of intoxication upon future drug intake, and reversal of lethality from drug overdose in rodent models5-10. Here, immunopharmacotherapy has been proven effective, and consequently, the pursuit of mAb therapeutics for nicotine and cocaine has advanced into clinical trials1,2,11. All of the drugs previously targeted by immunopharmacotherapy produce gross symptoms of intoxication that obstruct an examination of more subtle drug-induced cognitive deficits. Alternatively, Ntrk1 the CNS depressant flunitrazepam (Fig. 1A) was selected for this study because of its ability to effect higher order cognitive processes and its suitability for immunopharmacotherapy as a DEA Schedule IV abused substance12. Flunitrazepam binds with high affinity to benzodiazepine sites (BZ1and BZ2+) on GABA receptors to allosterically modulate GABA neurotransmission13. The requirement for pre-existing GABAergic tone for flunitrazepam-induced intoxication reinforces the coabuse of flunitrazepam with other drugs by potentiating the effect of GABA receptor agonists14. Indeed, addicts often combine flunitrazepam with other substances to temper a given drug high, or to self-medicate during drug.